Outcomes of neoadjuvant gemcitabine plus S‐1 and radiation therapy for borderline resectable pancreatic cancer

The efficacy of multidisciplinary treatment, including neoadjuvant treatment, in borderline resectable pancreatic cancer (BRPC) remains unclear. We assessed the efficacy of neoadjuvant chemoradiotherapy with gemcitabine and tegafu/gimearcil/oteracil (S‐1) for BRPC.

• Publication year

  2022

• Venue

  Journal of hepato-biliary-pancreatic sciences

• Publication date

  2022-09-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jhbp.1245PMID 36178433
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.

  2020cited by this paper
• Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).

  2019cited by this paper
• A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study

  2018cited by this paper
• Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial

  2018cited by this paper
• Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer

  2017cited by this paper
• Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact

  2016cited by this paper
• Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting

  2016cited by this paper
• Neoadjuvant Therapy for Pancreatic Cancer: Systematic Review of Postoperative Morbidity, Mortality, and Complications

  2016cited by this paper
• Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).

  2016cited by this paper
• Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement.

  2016cited by this paper
• National Comprehensive Cancer Network Resectability Status for Pancreatic Carcinoma Predicts Overall Survival

  2015cited by this paper
• Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment

  2015cited by this paper
• Improved survival with combined gemcitabine and S‐1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies

  2014cited by this paper
• Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.

  2013cited by this paper
• Neoadjuvant Chemotherapy with Gemcitabine and S-1 for Resectable and Borderline Pancreatic Ductal Adenocarcinoma: Results from a Prospective Multi-institutional Phase 2 Trial

  2013cited by this paper
• Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

  2013cited by this paper
• Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.

  2013cited by this paper
• Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: a multi-institutional survey by the Japanese Society of Pancreatic Surgery

  2013cited by this paper
• Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.

  2012cited by this paper
• FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

  2011cited by this paper
• Comparison of the pharmacokinetics and pharmacodynamics of S‐1 between Caucasian and East Asian patients

  2011cited by this paper
• Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.

  2010cited by this paper
• A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer

  2009cited by this paper
• Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement

  2009cited by this paper
• TNM Classification of Malignant Tumours, 7th Edition

  2009cited by this paper
• Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.

  2008cited by this paper
• Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.

  2008cited by this paper
• Surgery for pancreatic cancer: recent controversies and current practice.

  2005cited by this paper
• Effect of Neoadjuvant Chemoradiation on Operative Mortality and Morbidity for Pancreaticoduodenectomy

  2004cited by this paper
• The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists.

  2001cited by this paper
• The RECIST criteria: implications for diagnostic radiologists

  2001cited by this paper
• Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas.

  1992cited by this paper

• To Evaluate Whether Pretreatment CA19 ‐9 and DUPAN ‐2 Levels Can Serve as Predictive Markers to Guide the Choice Between NAT and Upfront Surgery in Pancreatic Cancer

  2025cites this paper
• Role of neoadjuvant chemo-radiotherapy for resectable and borderline resectable pancreatic adenocarcinoma- A systematic review and meta-analysis.

  2025cites this paper
• Endoscopic biliary drainage with multi-hole self-expandable metallic stent during neoadjuvant chemoradiotherapy in pancreatic cancer

  2025cites this paper
• The clinical outcomes of adjuvant gemcitabine plus S-1 in resected pancreatic cancer: a single-center retrospective study

  2025influential citation
• Reconsideration of the clinical impact of neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: A dual-institution collaborative clinical study.

  2024cites this paper
• Clinical significance and therapeutic implication of CD200 in pancreatic cancer.

  2024cites this paper
• Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic Adenocarcinoma

  2023cites this paper
• Predictive impacts of peritoneal washing cytology for surgical resection‐intended pancreatic cancer cases: Establishment of planned staging laparoscopy criteria

  2023cites this paper
• Total neoadjuvant therapy improves survival of patients with borderline resectable pancreatic cancer with arterial involvement

  2023influential citation